Fc domain enhanced anti-TREM2 monoclonal antibody was shown to impair tumor growth in mice by enhancing anti-tumor CD8 T cell responses and altering the balance between immunosuppressive and immunostimulatory macrophages134. This evidence concerns the gene CD8A and neoplasm.